Published in J Clin Oncol on September 08, 2015
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC | NCT04849377
HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J Clin Invest (2016) 0.81
Modulation of the DNA damage response during the life cycle of human papillomaviruses. Virus Res (2016) 0.81
Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer. J Otolaryngol Head Neck Surg (2016) 0.81
Epithelial-to-Mesenchymal Transition in the Pathogenesis and Therapy of Head and Neck Cancer. Cancers (Basel) (2017) 0.80
Epigenetics of oropharyngeal squamous cell carcinoma: opportunities for novel chemotherapeutic targets. J Otolaryngol Head Neck Surg (2017) 0.79
Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine. Genes Cancer (2016) 0.79
Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Oropharynx. Head Neck Pathol (2017) 0.78
Update from the 4th Edition of the World Health Organization of Head and Neck Tumours: Tumours of the Oral Cavity and Mobile Tongue. Head Neck Pathol (2017) 0.78
Control of human papillomavirus gene expression by alternative splicing. Virus Res (2016) 0.78
Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. Nat Genet (2016) 0.78
Clinical features and treatment strategy for HPV-related oropharyngeal cancer. Int J Clin Oncol (2016) 0.77
Human polyomavirus and human papillomavirus prevalence and viral load in non-malignant tonsillar tissue and tonsillar carcinoma. Med Microbiol Immunol (2016) 0.76
Human Papillomavirus E2 Protein: Linking Replication, Transcription, and RNA Processing. J Virol (2016) 0.76
Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx. J Clin Oncol (2016) 0.76
Keratinocyte Differentiation-Dependent Human Papillomavirus Gene Regulation. Viruses (2017) 0.75
Development of a Full-Thickness Human Gingiva Equivalent Constructed from Immortalized Keratinocytes and Fibroblasts. Tissue Eng Part C Methods (2016) 0.75
EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Mol Cancer Ther (2016) 0.75
Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer. Cancer Prev Res (Phila) (2015) 0.75
Transoral robotic surgery with radial forearm free flap reconstruction: case control analysis. J Otolaryngol Head Neck Surg (2017) 0.75
Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. Int J Radiat Oncol Biol Phys (2016) 0.75
Morphologic diversity in human papillomavirus-related oropharyngeal squamous cell carcinoma: Catch Me If You Can! Mod Pathol (2017) 0.75
DEK associates with tumor stage and outcome in HPV16 positive oropharyngeal squamous cell carcinoma. Oncotarget (2017) 0.75
The evolution of sex-specific virulence in infectious diseases. Nat Commun (2016) 0.75
Impact of HPV infection on oral squamous cell carcinoma. Oncotarget (2016) 0.75
Is immunohistochemical evaluation of p16 in oropharyngeal cancer enough to predict the HPV positivity? Rep Pract Oncol Radiother (2017) 0.75
The interaction between human papillomavirus and other viruses. Virus Res (2016) 0.75
HPV disease transmission protection and control. Microb Cell (2016) 0.75
Association of serum cytokines with oral HPV clearance. Cytokine (2016) 0.75
The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer (2016) 0.75
The association of medication use with clearance or persistence of oral HPV infection. Cancer Causes Control (2016) 0.75
Distribution and factors associated with salivary secretory leukocyte protease inhibitor concentrations. Oral Dis (2016) 0.75
TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma. Cancer (2017) 0.75
No evidence for the presence of Epstein-Barr virus in squamous cell carcinoma of the mobile tongue. PLoS One (2017) 0.75
Psychosocial Issues in Patients with Head and Neck Cancer: an Updated Review with a Focus on Clinical Interventions. Curr Psychiatry Rep (2017) 0.75
Barriers to generating PDX models of HPV-related head and neck cancer. Laryngoscope (2017) 0.75
Human papillomavirus in head and neck squamous cell carcinoma: A descriptive study of histologically confirmed cases at Kamuzu Central Hospital in Lilongwe, Malawi. Malawi Med J (2017) 0.75
Prognostic modeling of oral cancer by gene profiles and clinicopathological co-variables. Oncotarget (2017) 0.75
Mechanisms by which HPV Induces a Replication Competent Environment in Differentiating Keratinocytes. Viruses (2017) 0.75
p16, HPV, and Cetuximab: What Is the Evidence? Oncologist (2017) 0.75
Listeria monocytogenes CadC regulates cadmium efflux and fine-tunes lipoprotein localization to escape the host immune response and promote infection. J Infect Dis (2017) 0.75
Prognostic Impact of AJCC/UICC 8th Edition New Staging Rules in Oropharyngeal Squamous Cell Carcinoma. Front Oncol (2017) 0.75
Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer. Cancer (2017) 0.75
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol (2012) 9.28
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst (2013) 8.75
Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst (2008) 8.70
Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol (2008) 7.97
Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA (2014) 6.42
Prevalence of oral HPV infection in the United States, 2009-2010. JAMA (2012) 6.02
Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer (2006) 3.38
Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet (2013) 3.25
Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol (2013) 3.00
Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87
Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst (2010) 2.81
HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol (2014) 2.41
Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region. Head Neck (2012) 2.40
Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst (2011) 2.18
The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) (2015) 2.17
Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer (2010) 2.08
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One (2013) 2.03
Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health (2014) 2.02
Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol (2014) 1.88
Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol (2012) 1.81
Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res (2012) 1.76
Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol (2009) 1.70
Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev (2011) 1.68
Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine (2012) 1.68
Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis (2002) 1.66
Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine (2010) 1.57
The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18-30 years. Sex Transm Dis (2012) 1.51
Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis (2012) 1.48
EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer (2014) 1.44
Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: Increasing incidence, but not in young adults. Oral Oncol (2009) 1.41
Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int J Cancer (2012) 1.31
Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J Natl Cancer Inst (2013) 1.29
Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations. Cancer Prev Res (Phila) (2011) 1.27
Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer (2013) 1.25
Role of human papillomavirus in non-oropharyngeal head and neck cancers. Oral Oncol (2013) 1.24
Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS One (2014) 1.20
Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol (2014) 1.16
Teaching moment: why promising biomarkers do not always translate into clinically useful tests. J Clin Oncol (2013) 1.12
Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol (2013) 1.11
Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985-2006. Ann R Coll Surg Engl (2010) 1.08
Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States. Emerg Infect Dis (2014) 1.04
Time trends in pharyngeal cancer incidence in Norway 1981-2005: a subsite analysis based on a reabstraction and recoding of registered cases. Cancer Causes Control (2010) 1.02
Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain (1990-2009). Int J Cancer (2013) 1.01
Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica. J Infect Dis (2013) 0.99
Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting. N Engl J Med (2013) 0.96
NHANES 2009-2012 Findings: Association of Sexual Behaviors with Higher Prevalence of Oral Oncogenic Human Papillomavirus Infections in U.S. Men. Cancer Res (2015) 0.96
Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time. Chem Res Toxicol (2014) 0.96
The use of ultrasound in the search for the primary site of unknown primary head and neck squamous cell cancers. Oral Oncol (2014) 0.96
Prevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysis. BMC Cancer (2014) 0.95
Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992-2009. Cancer Causes Control (2012) 0.94
Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection. J Infect Dis (2014) 0.94
Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol Head Neck Surg (2014) 0.92
Incidence trends of human papillomavirus-related head and neck cancer in Taiwan, 1995-2009. Int J Cancer (2014) 0.90
Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis. Cancer Epidemiol Biomarkers Prev (2015) 0.89
Concordant Oral-Genital HPV Infection in South Africa Couples: Evidence for Transmission. Front Oncol (2013) 0.88
Sexual transmission of oral human papillomavirus infection among men. Cancer Epidemiol Biomarkers Prev (2014) 0.87
Markers of HPV infection and survival in patients with head and neck tumors. Int J Cancer (2013) 0.86
Risk factors for oral human papillomavirus in heterosexual couples in an African setting. J Infect (2013) 0.84
Oral Human Papillomavirus (HPV) Infection among Unvaccinated High-Risk Young Adults. Cancers (Basel) (2014) 0.83
Human papillomavirus prevalence is high in oral samples of patients with tonsillar and base of tongue cancer. Oral Oncol (2014) 0.82
Transcervical ultrasonography is feasible to visualize and evaluate base of tongue cancers. PLoS One (2014) 0.82
Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025. Oral Oncol (2015) 0.81
Oral human papillomavirus infection in men who have sex with men with anal squamous intraepithelial lesions. Head Neck (2015) 0.76